

## MEDC

### PT Medco Energy Internasional Tbk.

#### Next Phase

- Production to rebound with 2H25 guidance of 155-160 mboepd, driven by Corridor PSC consolidation (+25 mboepd) and new tie-ins.
- 1H25 results showed resilience with USD623m EBITDA (54.7% margin) and low USD8.5/boe cash cost, despite net profit falling to USD37m.
- AMMN downstream ramp-up adds medium-term upside, with first 18.5kt copper cathode sales at USD9,808/t and full smelter utilization by FY26.
- Maintain BUY with TP of Rp 1,500, reflecting 4.2x EV/EBITDA 2026F.

#### From Price Pressure to Volume Power

Brent crude averaging USD70/bbl in 1H25 (-14% YoY) and still expected to remain range-bound as OPEC+ output discipline offsets fragile demand recovery in China and OECD markets, with MEDC's realized oil price at USD69.5/bbl (vs. USD80.8/bbl in 1H24). Gas realizations stayed firm at USD7.0/mmbtu, supporting production of 143 mboepd (-7% YoY) despite Senoro maintenance and weaker seasonal demand. Looking ahead, management guides 155-160 mboepd in 2H25, underpinned by the acquisition of Repsol's 24% WI in Corridor PSC (USD425m, closed July 2025), lifting MEDC's stake to ~70%. Corridor contributed ~51 mboepd in 1H25, and full consolidation is expected to add ~25 mboepd from 3Q25 and ~USD145m to FY26F EBITDA, while extending the reserve life to 10.7 years with a 5-year RRR of 163%. With additional projects (Forel/Terubuk, Suban Phase-2, Bisat-C), MEDC is shifting from price leverage toward volume-driven, gas-weighted earnings stability.

#### A Tough Quarter, but Resilience Intact

MEDC's 1H25 revenue was USD1.14bn (-2% YoY), in-line with our estimates (Ajaib: 47.8%), broken down into oil & gas 91.2%, power 8.0%, services 1.1%. EBITDA came in at USD623m (-4% YoY) with a still-solid 54.7% margin (vs 55.8% in 1H24), while net income fell to USD37m (-81.5% YoY), below our estimates (Ajaib: 15.6%) due to weaker oil realizations, USD8.9m dry-hole costs, and Amman Mineral's USD31m net loss from smelter commissioning delays. On a quarterly basis, 2Q25 revenue was USD578m (+3% QoQ, -5% YoY), EBITDA USD291m (-13% QoQ, -10% YoY), and net profit USD20m (+11% QoQ, -85% YoY). Importantly, oil & gas cash costs were contained at USD8.5/boe, ensuring resilience at current oil prices. Capex totaled USD193m in 1H25, allocated to Oman Block 60 drilling, Natuna and Corridor developments, and renewables. The balance sheet remained solid, with net debt reduced to USD2.1bn (-2.5% YoY), and net debt/EBITDA steady at ~1.8-2.1x. Sequential earnings recovery is expected in 2H25 as Corridor volumes and domestic gas demand pick up.

#### Renewables Rise as Amman Downstream Turns On

Power sales were 1,994 GWh in 1H25 (flat YoY), supported by new capacity from Ijen Geothermal (35 MW, Feb-25) and East Bali Solar (25 MWp, Jun-25). MEDC is targeting 4,300 GWh sales in FY25 and 500 MW solar by 2030, which should lift renewables' share toward 30% mix. AMMN is the medium-term catalyst: 1H25 copper output was 89 Mlbs and gold 60 Koz (vs. 236 Mlbs/495 Koz in 1H24), due to transition to downstream operations. In July, AMMN achieved first copper cathode output of 19.8kt, with 18.5kt sold at USD9,808/t, and produced its first refined gold. 3Q25 will mark the first full quarter of cathode export, and by FY26, full ramp-up of smelter & refinery should drive a step-change in AMMN profitability, reversing its 1H25 losses into strong cash flow contribution.

#### Maintain BUY with Higher TP

We maintain BUY on MEDC with higher target price of **Rp1,500** (previous TP: Rp1,350), implying 4.2x FY26F EV/EBITDA (-0.25 std deviation 5-year historical). Looking forward, three drivers should underpin re-rating: (1) production growth to 160 mboepd in 2H25 and beyond, led by Corridor expansion, (2) rising AMMN earnings as downstream assets stabilize in FY26, and (3) renewables expansion toward 30% capacity mix by 2030. **Key risk:** oil and gas price volatility that may pressure earnings, potential delays in AMMN's smelter ramp-up, and production risks from downtime or project execution slippage.

#### Key Financial Highlights


Key Metrics (USD mn)	2023	2024	2025F	2026F	2027F
Revenue	2,249	2,399	2,338	2,594	2,637
EBITDA	1,245	1,264	1,171	1,342	1,332
Net Profit	331	367	239	323	334
EPS Growth (%)	-36.5	16.1	-32.9	35.4	3.5
P/E (x)	5.78	4.74	9.62	7.11	6.87
P/BV (x)	0.94	0.74	1.01	1.02	0.91
EV/EBITDA (x)	4.18	4.20	4.56	4.08	4.17

## BUY

#### Stock Information (as of August 28, 2025)

Last Price (Rp)	1,195
Target Price (Rp)	1,500
Potential Upside	25.5%
Market Cap (Rp tn)	30.0
52 Week Range (Rp)	1,540 – 875
Free Float	24.7%
Share Out. (bn)	25.1
Beta	1.5

#### Stock Performance Comparison vs JCI



#### Shareholders

MEDC's Shareholders	Percentage
PT Medco Daya Abadi Lestari	51.50%
Public	23.53%
Diamond Bridge Pte. Ltd	21.46%
Treasury Shares	1.80%
Warkat	0.33%

#### Company Description

##### MEDC's Company Profile

PT Medco Energi Internasional Tbk is an Indonesia-based southeast Asian energy and natural resources company. The Company is focused on three key business sectors: Oil & Gas, Clean Power and Copper & Gold Mining. The Company produces oil and gas primarily in Indonesia as well as in Oman, Thailand and Yemen.

#### Analyst


Rizal Rafly  
[rizal.rafly@ajaib.co.id](mailto:rizal.rafly@ajaib.co.id)

Figure 1. MEDC's 1H25 Financial Results

Key Metrics (USD mn)	1H25	1H24	YoY	2Q25	1Q25	QoQ	2Q24	YoY	2025F	% to Est
Revenue	1,138.40	1,165.40	-2.3%	577.9	560.5	3.1%	609	-5.1%	2,338	48.7%
Gross Profit	435.8	451.3	-3.4%	206.5	229.3	-9.9%	218.7	-5.6%	848	51.4%
Gross Margin (%)	38.3%	38.7%		35.7%	29.5%		35.9%			
EBITDA	623	650	-4.2%	291	332	-12.3%	321.9	-9.6%	1,171	53.2%
EBITDA Margin (%)	54.7%	55.8%		50.4%	43.7%		52.9%			
Net Profit	37.2	201	-81.5%	19.6	18	11.4%	128	-84.7%	239	15.6%
Net Margin (%)	3.3%	17.2%		3.4%	23.2%		21.1%			


Source: Company, Ajaib Research

Figure 2. Oil and Gas Production




Source: Company, Ajaib Research

Figure 4. Average Selling Price Projection




Source: Company, Ajaib Research

Figure 6. Power Sales Projection




Source: Company, Ajaib Research

Figure 3. Revenue Breakdown




Source: Company, Ajaib Research

Figure 5. Cash Cost Projection



Source: Company, Ajaib Research

Figure 7. EV/EBITDA Band MEDC



Source: Bloomberg, Ajaib Research



**Rating for Sectors:**

Overweight : We expect the industry to perform better than the primary market index (JCI) over the next 12 months.

Neutral : We expect the industry to perform in line with the primary market index (JCI) over the next 12 months.

Underweight : We expect the industry to underperform the primary market index (JCI) over the next 12 months.

**Rating for Stocks:**

Buy : The stock is expected to give total return (price appreciation + dividend yield) of > +10% over the next 12 months.

Hold : The stock is expected to give total return of > 0% to ≤ +10% over the next 12 months.

Sell : The stock is expected to give total return of < 0% over the next 12 months.

Outperform : The stock is expected to do slightly better than the market return. Equal to “moderate buy”

Underperform : The stock is expected to do slightly worse than the market return. Equal to “moderate sell”

**Analyst Certification:**

The lead analyst(s) who prepared this equity research report confirm that the opinions stated herein genuinely represent their personal perspectives regarding all the securities or issuers discussed. Additionally, the analyst(s) assert that their remuneration was not, is not, and will not be tied, either directly or indirectly, to any specific recommendations or viewpoints presented in this report.

PREPARED BY AJAIB RESEARCH TEAM



**DISCLAIMER**

This research report is published by PT Ajaib Sekuritas Asia and is based on information from sources that we believe to be reliable but have not been independently verified. We have taken all reasonable care to ensure that information contained herein is not untrue or misleading at the time of publication, however PT Ajaib Sekuritas Asia makes no representation as to its accuracy or completeness and it should not be solely relied upon. This research report is provided for the Investors of PT Ajaib Sekuritas Asia. Research reports which contain opinions may change anytime without any obligation for PT Ajaib Sekuritas Asia to notify any party. This research report is not intended for media publication. The media is not allowed to quote this research report in any article whether in full or in parts without permission from PT Ajaib Sekuritas Asia. For further information, the media can contact PT Ajaib Sekuritas Asia if they wish to refer to this research report.

This research report was prepared, approved, published and distributed by PT Ajaib Sekuritas Asia. This research report is not a recommendation, invitation, or order to make any investment decisions, including but not limited to, buy or sell certain investment products. Any investment decision made by the Investor will be the sole responsibility of the Investor, and PT Ajaib Sekuritas Asia nor any officer or employee of PT Ajaib Sekuritas Asia are not responsible for any losses that may occur due to the Investor's investment decision.